EcoDrugPlus

Adenosine A1 Receptor

Ensembl ID : ENSPVAG00000003222
Gene Symbol: ADORA1
1 Cross references
269 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSPVAG00000011399
Gene Symbol: ADORA2A
1 Cross references
260 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSPVAG00000017060
Gene Symbol: ADORA2B
1 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSPVAG00000007436
Gene Symbol: ADA
1 Cross references
216 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSPVAG00000017486
Gene Symbol: ADRA1A
1 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSPVAG00000011884
Gene Symbol: ADRA1B
1 Cross references
263 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSPVAG00000002816
Gene Symbol: ADRA1D
1 Cross references
194 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSPVAG00000017405
Gene Symbol: ADRB2
1 Cross references
263 Possible Orthologues:

Adrenoceptor Beta 3

Ensembl ID : ENSPVAG00000006012
Gene Symbol: ADRB3
1 Cross references
215 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSPVAG00000005152
Gene Symbol: AGER
1 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSPVAG00000015850
Gene Symbol: ADH5
1 Cross references
401 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSPVAG00000014254
Gene Symbol: AKR1B1
1 Cross references
427 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).